Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders held by Shanghai Yinos Biotech Co., Ltd., confirming that there were no rejected proposals [1] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a combination of on-site and online voting methods [2] - All current directors and supervisors attended the meeting, ensuring full representation of the board [3] Group 2 - Two key proposals were approved during the meeting: the reappointment of the accounting firm and the purchase of directors and officers liability insurance [4] - The meeting was held on September 23, 2025, at the designated location in Shanghai [4] - The voting results indicated that all proposals received more than half of the valid voting rights from attending shareholders, with separate counting for minority investors [5] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm, confirming that the procedures and voting methods adhered to legal requirements [5]
上海益诺思生物技术股份有限公司2025年第三次临时股东大会决议公告